Amorphous formulations for dissolution and bioavailability enhancement of poorly soluble APIs

Powder Technology

Volumn 285, Issue , 2015, Pages 2-15

  Kanaujia, P ^a   Poovizhi, P ^a,b   Ng, W K ^a,b   Tan, R B H ^a,b  

^a INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Amorphous formulation; Dissolution enhancement; Solid dispersion

Indexed keywords

BIOCHEMISTRY; CRYSTALLINE MATERIALS; DRUG DOSAGE; DRUG PRODUCTS; ENERGY UTILIZATION; MELT SPINNING; STABILIZATION;

ACTIVE PHARMACEUTICAL INGREDIENTS; BIOAVAILABILITY ENHANCEMENTS; ENVIRONMENTAL CONSIDERATIONS; PHARMACEUTICAL DOSAGE FORMS; PHARMACEUTICAL INDUSTRY; SOLID DISPERSION; STABILITY ENHANCEMENT; SUPERCRITICAL ANTISOLVENTS;

DISSOLUTION;

ACTIVE PHARMACEUTICAL INGREDIENT; CHEMICALS AND DRUGS; DRUG CARRIER; INORGANIC CARRIER; MESOPOROUS MAGNESIUM CARBONATE CARRIER; MESOPOROUS SILICA CARRIER; NEW CHEMICAL ENTITY; POLYMERIC CARRIER; POROUS CARRIER; UNCLASSIFIED DRUG;

AMORPHOUSFORM; COOLING; CRYSTALLIZATION; DISPERSION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SOLUBILITY; DRUG STABILITY; ELECTROSPINNING; EVAPORATION; FREEZE DRYING; FUSION METHOD; HOTE MELT EXTRUSION; PHARMACOLOGIC STRESS TESTING; POLYMERIZATION; PRECIPITATION; REVIEW; SHELF LIFE; SPRAY COATING; SPRAY DRYING; SUPERCRITICAL FLUID TECHNOLOGY;

EID: 84942197969     PISSN: 00325910     EISSN: 1873328X     Source Type: Journal    
DOI: 10.1016/j.powtec.2015.05.012     Document Type: Review

References (102)

1. Brown D. Unfinished business: target-based drug discovery. Drug Discov. Today 2007, 12:1007-1012.
2. Lipinski C. Poor aqueous solubility-an industry wide problem in drug discovery. Am. Pharm. Rev. 2002, 5:82-85.
3. Noyes A., Whitney W.R. The rate of dissolution of solid substances in their own solutions. J. Am. Chem. Soc. 1897, 19:930-934.
4. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug cilostazol in beagle dogs. J. Control. Release 2006, 111:56-64.
5. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 2004, 3:785-796.
6. Serajuddin A.T. Salt formation to improve drug solubility. Adv. Drug Deliv. Rev. 2007, 59:603-616.
7. Agrawal A.G., Kumar A., Gide P.S. Formulation of solid self-nanoemulsifying drug delivery systems using N-methyl pyrrolidone as cosolvent. Drug Dev. Ind. Pharm. 2015, 41:594-604.
8. Coffman R., Kildsig E.D.O. Hydrotropic solubilization-mechanistic studies. Pharm. Res. 1996, 13:1460-1463.
9. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996, 85:1017-1025.
10. Porter C.J., Trevaskis N.L., Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 2007, 6:231-248.
11. Serajuddin A.T. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88:1058-1066.
12. Shah S., Maddineni S., Lu J., Repka M.A. Melt extrusion with poorly soluble drugs. Int. J. Pharm. 2013, 453:233-352.
13. Hancock B.C., Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 1997, 86:1-12.
14. RodríGuez-Spong B., Price C.P., Jayasankar A., Matzger A.J., RodríGuez-Hornedo N.R. General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv. Drug Deliv. Rev. 2004, 56:241-274.
15. Guo Y., Shalaev E., Smith S. Physical stability of pharmaceutical formulations: solid-state characterization of amorphous dispersions. TrAC, Trends Anal. Chem. 2013, 49:137-144.
16. Hancock B.C., Carlson G.T., Ladipo D.D., Langdon B.A., Mullarney M.P. Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. Int. J. Pharm. 2002, 241:73-85.
17. Parks G.S., Huffman H.M., Cattor F.R. Studies on glass II: the transition between the glassy and liquid states in the case of glucose. J. Phys. Chem. 1928, 32:1366-1379.
18. Hancock B.C., Parks M. What is the true solubility advantage for amorphous pharmaceuticals?. Pharm. Res. 2000, 17:397-404.
19. Murdande S.B., Pikal M.J., Shanker R.M., Bogner R.H. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm. Res. 2010, 27:2704-2714.
20. Sekiguchi K., Obi N. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull. 1961, 9:866-872.
21. Vasconcelos T., Sarmento B., Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 2007, 12:1068-1075.
22. Simonelli A., Mehta S.C., Higuchi W.I. Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates. J. Pharm. Sci. 1969, 58:538-549.
23. Van Drooge D.J., Hinrichs W.L., Visser M.R., Frijlink H.W. Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques. Int. J. Pharm. 2006, 310:220-229.
24. Chiou W.L., Riegelman S. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 1971, 60:1281-1302.
25. Sun D.D., Lee P.I. Evolution of supersaturation of amorphous pharmaceuticals: the effect of rate of supersaturation generation. Mol. Pharm. 2013, 10:4330-4346.
26. Frank K.J., Rosenblatt K.M., Westedt U., Holig P., Rosenberg J., Magerlein M., Fricker G., Brandl M. Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: true supersaturation vs. apparent solubility enhancement. Int. J. Pharm. 2012, 437:288-293.
27. Serajuddin A.T., Sheen P.C., Mufson D., Bernstein D.F., Augustine M.A. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersions. J. Pharm. Sci. 1988, 77:414-417.
28. Dordunoo S.K., Ford J.L., Rubinstein M.H. Solidification studies of polyethylene glycols, gelucire 44/14 or their dispersions with triamterene or temazepam. J. Pharm. Pharmacol. 1996, 48:782-789.
29. Kanaujia P., Ng W.K., Tan R.B. Solid self-emulsifying drug delivery system (S-SEDDS) for improved dissolution rate of fenofibrate. J. Microencapsul. 2014, 31:293-298.
30. Ghebremeskel A.N., Vemavarapu C., Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions. Pharm. Res. 2006, 23:1928-1936.
31. Teja S.B., Patil S., Shete G., Patel S., Bansal A.K. Drug-excipient behavior in polymeric amorphous solid dispersions. J. E xcipi. Food Chem. 2013, 4:70-94.
32. Konno T. Physical and chemical changes of medicinals in mixtures with adsorbents in the solid state. IV. Study on reduced-pressure mixing for practical use of amorphous mixtures of flufenamic acid. Chem. Pharm. Bull. 1990, 38:2003-2007.
33. Lowell S., Shields J.E., Thomas M.A., Thommes M. Characterization of Porous Solids and Powders: Surface Area, Pore Size, and Density 2004, Kluwer Academic Publishers, Boston, Massachusetts. 2nd ed.
34. Vansant E.F., Van Dervoort P., Vrancken K.C. Characterization and Chemical Modification of the Silica Surface 1995, Elsevier, Amsterdam, The Netherlands. 1st ed.
35. Gupta M.K., Tseng Y.C., Goldman D., Bogner R.H. Hydrogen bonding with adsorbent during storage governs drug dissolution from solid-dispersion granules. Pharm. Res. 2002, 19:1663-1672.
36. Gupta M.K., Vanwert A., Bogner R.H. Formation of physically stable amorphous drugs by milling with Neusilin. J. Pharm. Sci. 2003, 92:536-551.
37. Kresge C.T., Leonowicz M.E., Roth W.J., Vartuli J.C., Beck J.S. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 1992, 359:710-712.
38. Zhao D., Huo Q., Feng J., Chmelka B.F., Stucky G.D. Nonionic triblock and star siblock copolymer and oligomeric surfactant syntheses of highly ordered, hydrothermally stable, mesoporous silica structures. J. Am. Chem. Soc. 1998, 120:6024-6036.
39. Shen S., Chow P.S., Chen F., Tan R.B. Submicron particles of SBA-15 modified with MgO as carriers for controlled drug delivery. Chem. Pharm. Bull. 2007, 55:985-991.
40. Shen S.C., Ng W.K., Chia L., Hu J., Tan R.B. Physical state and dissolution of ibuprofen formulated by co-spray drying with mesoporous silica: effect of pore and particle size. Int. J. Pharm. 2011, 410:188-195.
41. Van Speybroeck M., Mellaerts R., Mols R., Thi T.D., Martens J.A., Van Humbeeck J., Annaert P., Van Den Mooter G., Augustijns P. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. Eur. J. Pharm. Sci. 2010, 41:623-630.
42. Limnell T., Heikkila T., Santos H.A., Sistonen S., Hellsten S., Laaksonen T., Peltonen L., Kumar N., Murzin D.Y., Louhi-Kultanen M., Salonen J., Hirvonen J., Lehto V.P. Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles. Int. J. Pharm. 2011, 416:242-251.
43. Vialpando M., Aerts A., Persoons J., Martens J., Van Den Mooter G. Evaluation of ordered mesoporous silica as a carrier for poorly soluble drugs: influence of pressure on the structure and drug release. J. Pharm. Sci. 2011, 100:3411-3420.
44. Jia L., Shen J., Li Z., Zhang D., Zhang Q., Liu G., Zheng D., Tian X. In vitro and in vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes. Int. J. Pharm. 2013, 445:12-19.
45. Doadrio A.L., Sousa E.M., Doadrio J.C., Perez Pariente J., Izquierdo-Barba I., Vallet-Regi M. Mesoporous SBA-15 HPLC evaluation for controlled gentamicin drug delivery. J. Control. Release 2004, 97:125-132.
46. Prokopowicz M., Przyjazny A. Synthesis of sol-gel mesoporous silica materials providing a slow release of doxorubicin. J. Microencapsul. 2007, 24:682-701.
47. Zhang Y., Zhi Z., Jiang T., Zhang J., Wang Z., Wang S. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J. Control. Release 2010, 145:257-263.
48. Ambrogi V., Perioli L., Pagano C., Marmottini F., Ricci M., Sagnella A., Rossi C. Use of SBA-15 for furosemide oral delivery enhancement. Eur. J. Pharm. Sci. 2012, 46:43-48.
49. Zhang P., Forsgren J., Stromme M. Stabilisation of amorphous ibuprofen in Upsalite, a mesoporous magnesium carbonate, as an approach to increasing the aqueous solubility of poorly soluble drugs. Int. J. Pharm. 2014, 472:185-191.
50. Zallen R. The Physics of Amorphous Solids 2008, 1-23. John Wiley and Sons, New York.
51. El-Egakey M.A., Soliva M., Speiser P. Hot extruded dosage forms. I. Technology and dissolution kinetics of polymeric matrices. Pharm. Acta Helv. 1971, 46:31-52.
52. Kanaujia P., Lau G., Ng W.K., Widjaja E., Hanefeld A., Fischbach M., Maio M., Tan R.B. Nanoparticle formation and growth during in vitro dissolution of ketoconazole solid dispersion. J. Pharm. Sci. 2011, 100:2876-2885.
53. Tho I., Liepold B., Rosenberg J., Maegerlein M., Brandl M., Fricker G. Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media. Eur. J. Pharm. Sci. 2010, 40:25-32.
54. Zhang K., Yu H., Luo Q., Yang S., Lin X., Zhang Y., Tian B., Tang X. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension. Eur. J. Pharm. Biopharm. 2013, 85:1285-1292.
55. Maru S.M., De Matas M., Kelly A., Paradkar A. Characterization of thermal and rheological properties of zidovudine, lamivudine and plasticizer blends with ethyl cellulose to assess their suitability for hot melt extrusion. Eur. J. Pharm. Sci. 2011, 44:471-478.
56. Liu J., Cao F., Zhang C., Ping Q. Use of polymer combinations in the preparation of solid dispersions of a thermally unstable drug by hot-melt extrusion. Acta Pharmacol. Sin. B 2013, 3:263-272.
57. Fule R., Meer T., Sav A., Amin P. Solubility and dissolution rate enhancement of lumefantrine using hot melt extrusion technology with physicochemical characterisation. J. Pharm. Investig. 2013, 43:305-321.
58. J. Rosenberg, Breitenbach, J., The production of active substance compositions in the form of a solid solution of the active substance in a polymer matrix, and active substance compositions produced by this process. US Patent 5741519 (1998).
59. Breitenbach J. Melt extrusion can bring new benefits to HIV therapy: the example of Kaletra® tablets. Am. J. Drug Deliv. 2006, 4:61-64.
60. P. Holm, Buur, a, Elema, Mo, Møllgaard, B, Holm, Je, Schult, K, Controlled agglomeration, US Patent 7217431 (2007).
61. Dinunzio J.C., Brough C., Hughey J.R., Miller D.A., Williams R.O., Mcginity J.W. Fusion production of solid dispersions containing a heat-sensitive active ingredient by hot melt extrusion and Kinetisol dispersing. Eur. J. Pharm. Biopharm. 2010, 74:340-351.
62. Okamoto P., Lam N. Physics of crystal-to-glass transformations. Solid State Phys. 1999, 52:1-135.
63. Descamps M., Willart J.F., Dudognon E., Caron V. Transformation of pharmaceutical compounds upon milling and comilling: the role of T(g). J. Pharm. Sci. 2007, 96:1398-1407.
64. Caron V., Hu Y., Tajber L., Erxleben A., Corrigan O.I., Mcardle P., Healy A.M. Amorphous solid dispersions of sulfonamide/Soluplus(R) and sulfonamide/PVP prepared by ball milling. AAPS PharmSciTech 2013, 14:464-474.
65. Kang N., Lee J., Choi J.N., Mao C., Lee E.H. Cryomilling-induced solid dispersion of poor glass forming/poorly water-soluble mefenamic acid with polyvinylpyrrolidone K12. Drug Dev. Ind. Pharm. 2014, 1-11.
66. Hugo M., Kunath K., Dressman J. Selection of excipient, solvent and packaging to optimize the performance of spray-dried formulations: case example fenofibrate. Drug Dev. Ind. Pharm. 2013, 39:402-412.
67. Sethia S., Squillante E. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int. J. Pharm. 2004, 272:1-10.
68. Padden B.E., Miller J.M., Robbins T., Zocharski P.D., Prasad L., Spence J.K., Lafountaine J. Amorphous solid dispersions as enabling formulations for discovery and early development. Am. Pharm. Rev. 2011, 14:5-8.
69. Douroumis D., Bouropoulos N., Fahr A. Physicochemical characterization of solid dispersions of three antiepileptic drugs prepared by solvent evaporation method. J. Pharm. Pharmacol. 2007, 59:645-653.
70. Karanth H., Shenoy V.S., Murthy R.R. Industrially feasible alternative approaches in the manufacture of solid dispersions: a technical report. AAPS PharmSciTech 2006, 7:87.
71. Zhao M., Barker S.A., Belton P.S., Mcgregor C., Craig D.Q.M. Development of fully amorphous dispersions of a low Tg drug via co-spray drying with hydrophilic polymers. Eur. J. Pharm. Biopharm. 2012, 82:572-579.
72. Takeuchi H., Nagira S., Yamamoto H., Kawashima Y. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int. J. Pharm. 2005, 293:155-164.
73. Kumar S., Shen J., Burgess D.J. Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole. J. Control. Release 2014, 192:95-102.
74. Wu X., Hayes D., Zwischenberger J.B., Kuhn R.J., Mansour H.M. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. Drug Des. Devel. Ther. 2013, 7:59.
75. Gilis P.A., De Conde V., Vandecruys R. Beads Having a Core Coated with An Antifungal and A Polymer, US Patent 5633015 1997.
76. Zhang M., Li H., Lang B., O'Donnell K., Zhang H., Wang Z., Dong Y., Wu C., Williams Iii R.O. Formulation and delivery of improved amorphous fenofibrate solid dispersions prepared by thin film freezing. Eur. J. Pharm. Biopharm. 2012, 82:534-544.
77. Yu Z., Johnston K.P., Williams R.O. Spray freezing into liquid versus spray-freeze drying: influence of atomization on protein aggregation and biological activity. Eur. J. Pharm. Sci. 2006, 27:9-18.
78. Rogers T.L., Nelsen A.C., Sarkari M., Young T.J., Johnston K.P., Williams R.O. Enhanced aqueous dissolution of a poorly water soluble drug by novel particle engineering technology: spray-freezing into liquid with atmospheric freeze-drying. Pharm. Res. 2003, 20:485-493.
79. Tong H.H., Du Z., Wang G.N., Chan H.M., Chang Q., Lai L.C., Chow A.H., Zheng Y. Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS Class IV compound. Int. J. Pharm. 2011, 404:148-158.
80. Jang S.W., Kang M.J. Improved oral absorption and chemical stability of everolimus via preparation of solid dispersion using solvent wetting technique. Int. J. Pharm. 2014, 473:187-193.
81. Zhou L., Wang W., Feng Y., Wei S., Zhou J., Yu B., Shen J. Delivering a hydrophobic anticancer drug for photodynamic therapy by amorphous formulation. Bioorg. Med. Chem. Lett. 2010, 20:6172-6174.
82. Bhardwaj N., Kundu S.C. Electrospinning: a fascinating fiber fabrication technique. Biotechnol. Adv. 2010, 28:325-347.
83. Yu D.G., Gao L.D., White K., Branford-White C., Lu W.Y., Zhu L.M. Multicomponent amorphous nanofibers electrospun from hot aqueous solutions of a poorly soluble drug. Pharm. Res. 2010, 27:2466-2477.
84. Yu D.G., Branford-White C., White K., Li X.L., Zhu L.M. Dissolution improvement of electrospun nanofiber-based solid dispersions for acetaminophen. AAPS PharmSciTech 2010, 11:809-817.
85. Phillips E.M., Stella V.J. Rapid expansion from supercritical solutions: application to pharmaceutical processes. Int. J. Pharm. 1993, 94:1-10.
86. Subramaniam B., Rajewski R.A., Snavely K. Pharmaceutical processing with supercritical carbon dioxide. J. Pharm. Sci. 1997, 86:885-890.
87. Palakodaty S., York P. Phase behavioral effects on particle formation processes using supercritical fluids. Pharm. Res. 1999, 16:976-985.
88. Li S., Liu Y., Liu T., Zhao L., Zhao J., Feng N. Development and in-vivo assessment of the bioavailability of oridonin solid dispersions by the gas anti-solvent technique. Int. J. Pharm. 2011, 411:172-177.
89. Lim R.T.Y., Ng W.K., Tan R.B.H. Amorphization of pharmaceutical compound by co-precipitation using supercritical anti-solvent (SAS) process (part I). J. Supercrit. Fluids 2011, 53:179-184.
90. Kim M.S., Kim J.S., Park H.J., Cho W.K., Cha K.H., Hwang S.J. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int. J. Nanomedicine 2011, 6:2997-3009.
91. Park J.H., Yan Y.D., Chi S.C., Hwang D.H., Shanmugam S., Lyoo W.S., Woo J.S., Yong C.S., Choi H.G. Preparation and evaluation of Cremophor-free paclitaxel solid dispersion by a supercritical antisolvent process. J. Pharm. Pharmacol. 2011, 63:491-499.
92. M. Hanna, P. York, Method and apparatus for the formation of particles, World patent 9 501 221 (1995).
93. Juppo A.M., Boissier C., Khoo C. Evaluation of solid dispersion particles prepared with SEDS. Int. J. Pharm. 2003, 250:385-401.
94. Wu K., Li J., Wang W., Winstead D.A. Formation and characterization of solid dispersions of piroxicam and polyvinylpyrrolidone using spray drying and precipitation with compressed antisolvent. J. Pharm. Sci. 2009, 98:2422-2431.
95. Kazarian S.G., Martirosyan G.G. Spectroscopy of polymer/drug formulations processed with supercritical fluids: in situ ATR-IR and Raman study of impregnation of ibuprofen into PVP. Int. J. Pharm. 2002, 232:81-90.
96. Marsac P.J., Shamblin S.L., Taylor L.S. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm. Res. 2006, 23:2417-2426.
97. Bansal S.S., Kaushal A.M., Bansal A.K. Enthalpy relaxation studies of two structurally related amorphous drugs and their binary dispersions. Drug Dev. Ind. Pharm. 2010, 36:1271-1280.
98. Friesen D.T., Shanker R., Crew M., Smithey D.T., Curatolo W.J., Nightingale J.A. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol. Pharm. 2008, 5:1003-1019.
99. Gordon M., Taylor J.S. Ideal copolymers and the second-order transitions of synthetic rubbers. I. Non-crystalline copolymers. J. Appl. Chem. 1952, 2:493-501.
100. Van Den Mooter G., Wuyts M., Blaton N., Busson R., Grobet P., Augustijns P., Kinget R. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur. J. Pharm. Sci. 2001, 12:261-269.
101. Karavas E., Ktistis G., Xenakis A., Georgarakis E. Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone. Eur. J. Pharm. Biopharm. 2006, 63:103-114.
102. Maniruzzaman M., Morgan D.J., Mendham A.P., Pang J., Snowden M.J., Douroumis D. Drug-polymer intermolecular interactions in hot-melt extruded solid dispersions. Int. J. Pharm. 2013, 443:199-208.